Absolute Neutrophil Count — Infection Defence Marker

The absolute neutrophil count represents the actual number of mature and nearly mature neutrophils circulating within a microlitre of blood. Clinicians calculate this value by multiplying the total white blood cell count by the percentage of neutrophils, which includes segmented cells and less mature band cells. Neutrophils serve as the first line of defence in the innate immune system, migrating rapidly to sites of microbial invasion to engulf and neutralise pathogens.

In healthy adults, an ANC generally falls between 1,500 and 8,000 cells per microlitre. When cancer therapies suppress bone marrow activity, this number can drop below normal limits, producing a condition known as neutropenia. Severe neutropenia arises when the ANC falls below 500 cells per microlitre, dramatically escalating the susceptibility to opportunistic bacterial and fungal infections. Tracking the ANC allows haematologists and oncologists to identify marrow recovery or persistent suppression.

The ANC is critical because it dictates clinical safety boundaries throughout anti-cancer therapy. If a patient's ANC drops below designated thresholds, continuing full-dose chemotherapy could lead to neutropenic sepsis, a life-threatening medical emergency. Therefore, oncologists rely on the ANC to decide whether to proceed with scheduled infusions, delay a treatment cycle, or reduce therapeutic dosages. Tracking this value also alerts clinicians to prescribe protective measures, such as prophylactic antibiotics or granulocyte colony-stimulating factors (G-CSFs). For patients, understanding their ANC provides actionable insight into their current infection vulnerability, helping them practise appropriate hygiene, food safety, and social distancing.

The ANC is measured through a routine complete blood count (CBC) with differential, collected via a standard venous blood draw. The laboratory analyser identifies total white blood cells and categorises the distinct subtypes by percentage. Modern haematology laboratories calculate the ANC automatically, though a manual blood smear microscopy review may be conducted if abnormal or immature blast cells are detected. No specific preparation or fasting is needed for this test, which is typically performed shortly before every cycle of cytotoxic therapy.

The absolute neutrophil count is evaluated across virtually all cancer types where myelosuppressive therapies are prescribed. It is particularly prominent in haematological malignancies, including acute myeloid leukaemia, acute lymphoblastic leukaemia, non-Hodgkin lymphoma, and multiple myeloma, where the disease directly compromises bone marrow function. It is equally vital in solid tumours frequently managed with intensive cytotoxic chemotherapy regimens, such as breast cancer, ovarian cancer, non-small cell lung cancer, and gastrointestinal malignancies, where marrow suppression is an anticipated side effect of treatment.

A low ANC directly influences therapeutic scheduling and supportive care interventions. When levels fall below protocol thresholds (frequently 1,000 to 1,500 cells per microlitre), clinicians often pause chemotherapy to give bone marrow time to recover. To accelerate neutrophil production and maintain planned dosing intervals, doctors may prescribe growth factors such as filgrastim or pegfilgrastim. If a patient develops a fever during severe neutropenia, immediate hospitalisation and broad-spectrum intravenous antibiotic therapy are initiated without waiting for culture results.